Home > Insider Trading > Filing (0000908662-13-000291)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1177648	Enanta Pharmaceuticals Inc	ENTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1572051	E. Marc Goldberg	C/O Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown MA 02472		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2013-11-26	34,446	$25.61	570,021	No	4	S	Indirect	By BioVentures Investors Limited Partnership II
Common Stock	Disposition	2013-11-27	15,554	$26.08	554,467	No	4	S	Indirect	By BioVentures Investors Limited Partnership II

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By BioVentures Investors Limited Partnership II
No	4	S	Indirect	By BioVentures Investors Limited Partnership II

Footnotes

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.40 to $25.89, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.80 to $26.54, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2.
These shares are held by BioVentures Investors Limited Partnership II, and are shares for which Mr. Goldberg may be deemed to share voting and investment control. Mr. Goldberg disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.